세계의 심장 페이스메이커 시장 규모 : 유형별, 기술별, 용도별, 최종사용자별, 지역 범위별 및 예측

Cardiac Pacemaker Market Size And Forecast

Cardiac Pacemaker Market size was valued at USD 5.98 Billion in 2024 and is projected to reach USD 8.18 Billion by 2032, growing at a CAGR of 4.40% from 2026 to 2032.

The Cardiac Pacemaker Market is defined as the global industry involved in the research, development, manufacturing, and distribution of medical devices designed to regulate and normalize the heartbeat of a patient. These devices, primarily permanent or temporary electronic pulse generators, are surgically implanted or externally used to treat heart rhythm disorders, specifically bradycardia (abnormally slow heart rate), heart block, and certain types of arrhythmias. The fundamental purpose of the market is to supply life saving and life enhancing technology that monitors the heart's electrical activity and, when necessary, delivers precisely timed electrical impulses to stimulate the heart muscle and ensure a functional, regular rhythm.

The scope of this market encompasses a diverse range of products categorized chiefly by technology and implantability. Key segments include Implantable Pacemakers, which are further broken down into Single Chamber (pacing one heart chamber), Dual Chamber (pacing two chambers, the clinical workhorse), and Biventricular or CRT (Cardiac Resynchronization Therapy) devices used for advanced heart failure. A major area of innovation is the development and commercialization of Leadless Pacemakers, which are miniaturized, self contained capsules implanted directly into the heart wall via a catheter, eliminating the traditional leads (wires) and their associated complications. The market also includes External Pacemakers, which are temporary devices used in emergency or acute care settings.

Market growth is fundamentally propelled by the rising global incidence of cardiovascular diseases particularly those leading to bradyarrhythmias and the steady expansion of the aging population, as the need for pacing therapy increases significantly with age. This demand is further boosted by continuous technological advancements, such as the introduction of MRI compatible pacemakers and the integration of sophisticated remote monitoring capabilities. These features allow healthcare providers to track device performance and patient data in real time, improving long term management and clinical outcomes. Consequently, the market spans a value chain from large multinational device manufacturers (Medtronic, Abbott, Boston Scientific) to specialized cardiac centers, hospitals, and ambulatory surgical facilities that perform the implantation procedures.

Global Cardiac Pacemaker Market Drivers

The global cardiac pacemaker market is experiencing robust expansion, propelled by an unprecedented demographic shift, a worsening global health crisis related to heart disease, and continuous, life improving technological innovation. The confluence of these factors is creating a rapidly expanding patient pool and enhancing the adoption rates of advanced pacing devices across the globe. This analysis details the three fundamental drivers that are defining the market's trajectory and sustaining its growth momentum.

Aging Global Population: The exponential growth of the aging global population is the single most significant demographic driver of the cardiac pacemaker market, guaranteeing sustained long term demand. The World Health Organization's (WHO) projection that the population aged 60 and older will double to 2.1 billion by 2050 creates a colossal and consistent patient cohort. As established by the American Heart Association (AHA) in 2022, approximately 80% of pacemaker recipients are over 65 years old, a fact directly linking geriatric demographics to cardiac rhythm disorder incidence. Age related degeneration of the heart's electrical system, leading to conditions like sick sinus syndrome and atrioventricular (AV) block, necessitates pacemaker intervention. Furthermore, the high volume of procedures, exemplified by the 1 million annual pacemaker procedures in Europe as of 2021, and the 3.2% yearly increase in the elderly segment, underscores how this demographic shift is directly translating into higher implantation rates and driving market volume across developed economies and increasingly in emerging regions.

Rising Cardiovascular Disease Burden: The severe and rising global burden of cardiovascular diseases (CVDs) is a critical clinical driver, generating a massive pool of patients requiring rhythm management therapy. With the World Heart Federation's 2022 statistics indicating that CVDs cause 18.6 million deaths annually worldwide, the scale of heart health challenges is immense, and pacemakers are an essential part of the treatment spectrum for associated arrhythmias. Data from the European Society of Cardiology reveals the high prevalence of these treatable conditions, with arrhythmias affecting approximately 9% of people over 65, compared to just 2% in the under 65 group, highlighting the clear need for effective intervention. Even in highly developed healthcare systems like the US, where CDC data showed approximately 659,000 annual heart disease deaths in 2023, pacemakers remain life saving devices for bradycardia and certain forms of heart failure. The global persistence of risk factors like hypertension, diabetes, and obesity ensures that the patient population requiring cardiac rhythm management will continue to surge, cementing the demand for pacing technology.

Technological Advancements in Pacemaker Devices: Continuous technological advancements are a powerful market driver, not only enhancing patient outcomes but also expanding the clinical applicability and adoption of modern pacemaker systems. Innovations have significantly improved patient quality of life and procedure safety, leading to increased physician confidence and patient acceptance. The acceleration of this trend is evidenced by the FDA's approval of 15% more new pacemaker technologies in 2022 compared to 2020. Crucially, the introduction of features that address previous contraindications has dramatically expanded the addressable market; for instance, the American College of Cardiology reported in 2022 that MRI compatible pacemakers now represent over 75% of new implants. This innovation removes a major barrier to care, as the need for MRI diagnostic scanning is common. Moreover, the emergence of leadless pacemakers, which offer a minimally invasive, smaller profile alternative to traditional systems, and devices with remote patient monitoring capabilities that improve follow up care efficiency, are driving premium market growth and higher ASPs, thus propelling the cardiac pacemaker market forward.

Global Cardiac Pacemaker Market Restraints

While the global cardiac pacemaker market is fueled by an aging population and rising cardiovascular disease incidence, a significant set of restraints center around affordability and market access dynamics in developing nations. These factors pose a long term challenge to the premium pricing models of advanced medical device manufacturers. The following paragraphs detail the influence of increasing government investment, the rising role of NGOs, and shifting technology adoption trends in emerging markets, all of which pressure manufacturers toward more cost effective solutions and create a market headwind for high cost devices.

Increasing Government Healthcare Initiatives: The rapid expansion of government healthcare initiatives in developing nations acts as a long term market restraint by driving a systemic need for more affordable and localized pacemaker solutions, challenging the dominance of high cost devices. As the World Bank's 2023 data highlights, the commitment of USD 12.5 Billion in healthcare infrastructure loans to developing nations is translating into increased capacity for cardiac care but simultaneously empowers local governments to negotiate volume based pricing or favor devices with lower procurement costs. This trend is reinforced by the WHO's 2022 report of 45 developing nations implementing new cardiovascular healthcare programs with 25% average funding increases, which, coupled with the Global Health Initiative's USD 850 Million allocation for device accessibility, creates significant price pressure on multinational manufacturers. These initiatives effectively establish a larger, but more cost conscious, market segment, forcing top tier vendors to either lower prices or develop entirely new, simplified, and cost optimized devices to remain competitive in high growth regions like Asia Pacific and Africa. This downward pressure on Average Selling Price (ASP) restrains overall market revenue growth despite rising procedure volumes.

Rise in Non Governmental Organization (NGO) Support: The burgeoning role of Non Governmental Organizations (NGOs) in cardiac care access serves as a crucial restraint by supporting the adoption of low cost or refurbished pacemakers, thus diminishing the immediate revenue potential for new, high margin devices. The data illustrating the NGO supported 15,000 pacemaker implantations in developing nations in 2022 by organizations like the Heart to Heart International Foundation, and the overall 32% increase in cardiac care funding from 2020 2023, emphasizes a well funded alternative supply chain. These programs, which collectively reached approximately 2.5 million patients in underserved regions per 2023 WHO data, often rely on device donation, repurposing, or procurement of simpler, highly cost effective models. This large scale, ethical alternative market segment bypasses the conventional commercial sales channel for premium devices, directly capping the achievable market size and revenue per unit for high end pacemakers in regions where high income penetration is already limited. This trend compels manufacturers to either participate in these low revenue programs or accept a reduced market reach.

Technology Adoption in Emerging Markets: The rapid increase in technological adoption and infrastructural capacity within emerging markets restrains the cardiac pacemaker market by enabling local competitors and increasing demand for basic, high volume device models over complex, high margin innovations. The 28% increase in pacemaker installations in developing nations between 2020 and 2022, alongside the 45% rise in capable cardiac centers documented by the Asian Heart Association, confirms that market accessibility and surgical capability are rapidly improving. However, much of this growth is centered around basic, single chamber conventional pacemakers due to cost and local clinical familiarity. Furthermore, the expansion of mobile cardiac clinics serving 35% more patients in rural areas (2022 vs. 2020) signifies a volume focused shift in healthcare delivery. This acceleration of basic infrastructure creates a "good enough" scenario where demand for premium, feature rich devices (like Leadless or MRI compatible models) remains relatively slow compared to the surging demand for proven, highly reliable, and fundamentally cheaper unit

Global Cardiac Pacemaker Market Segmentation Analysis

The Global Cardiac Pacemaker Market is segmented based on Type, Application, Technology, End User, And Geography.

Cardiac Pacemaker Market, By Type

MRI compatible Pacemaker

Conventional Pacemaker

Implantable Pacemaker

Leadless Pacemaker

External Pacemaker

Biventricular Chamber

Based on Type, the Cardiac Pacemaker Market is segmented into MRI compatible Pacemaker, Conventional Pacemaker, Implantable Pacemaker, Leadless Pacemaker, External Pacemaker, and Biventricular Chamber. At VMR, our analysis of the market structure indicates that the Implantable Pacemaker segment is the foundational and overwhelming revenue leader, holding a dominant share of over 60% of the total market in 2024. This subsegment's dominance is driven by its necessity for long term, chronic cardiac rhythm management, particularly for conditions like symptomatic bradycardia, which affects a rapidly expanding global geriatric population.

This segment is bolstered by market drivers such as established regulatory pathways, favorable and widespread reimbursement policies in key markets like North America, and its essential reliance by primary end users, namely Hospitals and Cardiac Centers, which conduct the vast majority of pacemaker implantations. However, the most significant growth dynamic is captured within the MRI Compatible Pacemaker segment, which is increasingly viewed as the standard of care due to a compelling industry trend. As the general population ages, approximately 50% 75% of pacemaker patients will eventually require a Magnetic Resonance Imaging (MRI) scan for co morbidities like cancer, neurological, or musculoskeletal disorders, driving a massive clinical demand shift. This segment is projected to exhibit the highest CAGR (over 10%) through the forecast period, as major medical device manufacturers transition their entire portfolios to MRI conditional status to meet this regulatory and consumer demand, with its rapid adoption in developed regions like the US and Western Europe leading the charge. The remaining subsegments, including Conventional Pacemakers, which represent non MRI compatible legacy devices, are steadily losing market share but retain a residual presence in price sensitive or older patient populations; External Pacemakers fill a critical, high urgency niche for temporary cardiac stabilization in acute care settings; and the technologically advanced Leadless Pacemaker and specialized Biventricular Chamber devices (the latter used specifically for Cardiac Resynchronization Therapy in advanced heart failure) represent high growth, innovation driven areas poised to disrupt long term market dynamics with their focus on minimally invasive procedures and superior physiological outcomes.

Cardiac Pacemaker Market, By Technology

Single Chamber

Dual Chamber

Biventricular

Based on Technology, the Cardiac Pacemaker Market is segmented into Single Chamber, Dual Chamber, and Biventricular. At VMR, we observe that the Dual Chamber pacemaker segment is the current market dominator, consistently holding the largest revenue share, estimated to be around 45 50% in 2024, due to its clinical superiority in mimicking the heart's natural rhythm (atrioventricular synchrony). This segment's dominance is profoundly influenced by market drivers such as increasing clinical recommendations favoring dual chamber pacing for most bradyarrhythmias, leading to better patient outcomes and reduced incidence of "pacemaker syndrome." Regionally, the high adoption rate in North America, supported by robust insurance coverage and established medical guidelines, underpins its revenue contribution. Industry trends, including the integration of MRI compatible technology and digital remote monitoring capabilities in dual chamber devices by key players, further solidify its lead.

The Biventricular (or Cardiac Resynchronization Therapy, CRT P) segment stands as the second most dominant, but crucially, it is the fastest growing segment, projected to exhibit the highest CAGR (over 5% through 2034). Its growth is driven by the rising global prevalence of Congestive Heart Failure (CHF) with left bundle branch block, where CRT P is a guideline mandated, life saving therapy that significantly reduces mortality and hospitalization, making it indispensable for end users like specialized cardiac care centers. Furthermore, the push for AI supported diagnostics to improve patient selection for CRT in high growth markets like the Asia Pacific region is accelerating its adoption. The Single Chamber segment plays an essential supporting role, holding a substantial, albeit declining, share (approximately 20% 25% of the market), and its utility is largely confined to simpler ventricular only pacing needs or specific leadless pacemaker models, which are a strong technological trend offering reduced complication risk but are currently often single chamber only.

Cardiac Pacemaker Market, By Application

Arrhythmia

Atrial fibrillation

Heart Block

Long QT Syndrome

Congestive Heart Failure

Based on Application, the Cardiac Pacemaker Market is segmented into Arrhythmia, Atrial fibrillation, Heart Block, Long QT Syndrome, and Congestive Heart Failure. At VMR, we observe that the Arrhythmia segment, which often includes Bradycardia (slow heart rate), remains the dominant subsegment, historically commanding the largest market share, estimated to be around 35 40% of the total application revenue. This dominance is driven by the fact that bradycardia, a key indication for permanent pacing, is highly prevalent, particularly within the rapidly expanding global aging population; as individuals age, the natural wear and tear on the heart's electrical system, specifically the sinoatrial and atrioventricular nodes, makes pacemaker implantation a standard of care, life saving intervention. Market drivers include the increasing prevalence of Chronic Cardiovascular Diseases (CVDs), favorable reimbursement policies in North America and Europe, and the industry trend toward miniaturization, such as leadless pacemakers (LPs), which are driving higher patient adoption rates.

The second most dominant subsegment is Congestive Heart Failure (CHF), which is exhibiting the highest CAGR due to the growing clinical reliance on Cardiac Resynchronization Therapy Pacemakers (CRT P) to manage advanced heart failure. This application's growth is strongly supported by robust clinical evidence demonstrating improved quality of life and reduced hospitalization rates for select CHF patients, particularly in developed regions like North America where advanced diagnostic and treatment infrastructure is readily available, and new device approvals, such as advanced biventricular pacemakers, fuel revenue contribution. The remaining subsegments, Atrial fibrillation (AF), Heart Block, and Long QT Syndrome, play a crucial supporting role. While Arrhythmia broadly covers AF and Heart Block, dedicated pacemaker interventions for severe or congenital Heart Block provide a stable, yet niche market, and the rising incidence of AF (often leading to bradycardia requiring pacing) is a key growth area. Long QT Syndrome, while representing a smaller patient cohort, relies heavily on pacemakers in combination with Implantable Cardioverter Defibrillators (ICDs), indicating a future potential linked to the advancement and convergence of Cardiac Rhythm Management (CRM) device technologies.

Cardiac Pacemaker Market, By End User

Cardiac centers

Ambulatory surgical centers

Hospitals

Clinics

Based on End User, the Cardiac Pacemaker Market is segmented into Cardiac centers, Ambulatory surgical centers, Hospitals, and Clinics. At VMR, we observe that the Hospitals and Cardiac Centers segment is decisively dominant, collectively accounting for an estimated 60% to 70% of the total revenue share (with some sources citing over 70%) in the cardiac pacemaker market. This dominance is driven by several critical factors: the need for advanced, high cost infrastructure and specialized surgical teams for complex pacemaker implantation procedures; the rising global prevalence of cardiovascular diseases (CVDs), particularly among the geriatric population; and favorable reimbursement policies in major markets like North America and Europe, where hospitals serve as the primary point of care for critical cardiac interventions. Furthermore, Hospitals are key industries relying on this segment, as they are the main adoption venue for technological innovations like MRI compatible and leadless pacemakers, which integrate well with their existing advanced diagnostic and interventional cardiology departments, providing long term patient management and follow up care.

The Ambulatory Surgical Centers (ASCs) segment constitutes the second most dominant subsegment, positioned for the fastest growth with a projected CAGR exceeding 6.0% in the forecast period. The role of ASCs is rapidly expanding, focusing on cost effective, minimally invasive, same day pacemaker implantation procedures, driven by the increasing industry trend toward outpatient care, which reduces healthcare costs and patient recovery time. Regionally, North America is a strong market for ASCs, benefiting from specific regulatory changes and the drive for efficiency.

The remaining subsegments, Clinics and other specialized facilities, play a supporting role, primarily focusing on pre operative patient evaluation, post implantation device monitoring (often leveraging digitalization and remote patient monitoring trends), and routine follow up care. While their individual revenue contribution is smaller, their future potential lies in the integration of AI driven diagnostics and the growing adoption of telehealth services, which will enable them to manage a significant portion of the non invasive patient care pathway, thus unburdening the highly specialized hospital and cardiac center segment.

Cardiac Pacemaker Market, By Geography

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The global cardiac pacemaker market is a vital segment of the medical device industry, driven primarily by the rising prevalence of cardiovascular diseases (CVDs) such as arrhythmias and bradycardia, coupled with a globally aging population. Technological advancements, particularly in leadless and MRI compatible pacemakers, are transforming patient care. The geographical analysis of this market reveals significant disparities in market size, growth rates, and dynamics, largely influenced by healthcare infrastructure, reimbursement policies, and economic development levels across different regions.

United States Cardiac Pacemaker Market

Dynamics & Market Size: The market is highly mature and characterized by high procedural volume and spending on advanced medical devices. It benefits from a well established and sophisticated healthcare infrastructure.

Key Growth Drivers: A high prevalence of cardiovascular diseases and an advancing geriatric population (which has a higher incidence of heart rhythm disorders) are primary drivers. Furthermore, supportive and favorable reimbursement policies for cardiac procedures and devices play a crucial role.

Current Trends: The market shows a strong adoption of cutting edge technologies, including leadless pacemakers (e.g., Micra) and MRI compatible devices. The integration of remote patient monitoring (RPM) via connected pacemakers is a major trend, allowing for real time tracking and potentially reducing hospital visits. Key market players (Medtronic, Abbott, Boston Scientific) have a dominant presence, driving continuous innovation.

Europe Cardiac Pacemaker Market

Dynamics & Market Size: Europe possesses a highly developed healthcare system, especially in Western European countries like Germany, the UK, and France, leading to high adoption rates of advanced pacemakers.

Key Growth Drivers: A substantial and continuously aging population, along with a high burden of arrhythmias and bradycardia, fuels demand. Favorable government healthcare expenditure and well established reimbursement frameworks in many countries accelerate the adoption of new, often premium priced, technologies.

Current Trends: Similar to the U.S., there is a significant shift towards MRI compatible and leadless pacemakers. The market is also seeing increasing investment in R&D and a focus on integrating telehealth and AI based monitoring systems into cardiac rhythm management to improve patient outcomes and efficiency. Germany and the UK are typically the largest country level markets within the region.

Asia Pacific Cardiac Pacemaker Market

Dynamics & Market Size: The market is highly diverse, ranging from advanced economies (Japan, Australia) to rapidly emerging markets (China, India). Rapid urbanization and lifestyle changes are increasing the prevalence of CVDs. East Asia, particularly China and Japan, currently holds a large share due to better infrastructure.

Key Growth Drivers: The colossal and rapidly aging population (especially in Japan and China), increasing patient awareness of cardiac health, and significantly improving healthcare infrastructure and expenditure in developing countries are the main drivers. Government initiatives to expand healthcare access (e.g., India's Ayushman Bharat scheme) also drive adoption.

Current Trends: There is a growing demand for both high end leadless pacemakers (in developed markets) and more cost effective conventional devices (in developing and rural areas). Foreign manufacturers are actively expanding their presence, and there's a push for domestic manufacturing to address cost challenges. Technological adoption, including leadless technology, is accelerating in major economies.

Latin America Cardiac Pacemaker Market

Dynamics & Market Size: The market is moderately mature, with growth being driven by economic improvements and expanding healthcare access, though challenges like income disparity can limit the widespread adoption of premium devices. Brazil dominates the regional market due to its comparatively developed healthcare system and large patient pool.

Key Growth Drivers: The rising incidence of cardiovascular diseases, growing healthcare expenditure, and a focus on improving hospital infrastructure and specialized cardiac care facilities are fueling expansion.

Current Trends: The market is gradually adopting advanced technologies, with a strong demand for reliable implantable pacemakers. There is an increasing focus on adopting minimally invasive procedures and technologies. Mexico is also showing robust growth, supported by health reforms and improved access to treatments.

Middle East & Africa Cardiac Pacemaker Market

Dynamics & Market Size: The Middle East (especially the GCC countries like Saudi Arabia and the UAE) exhibits high healthcare spending and advanced infrastructure, driving the adoption of sophisticated devices. Africa, conversely, is largely constrained by lower healthcare spending and underdeveloped infrastructure, though the patient burden is rising.

Key Growth Drivers: A growing prevalence of lifestyle diseases (obesity, diabetes, which are risk factors for CVDs) in the Middle East, along with a continuous effort to modernize healthcare infrastructure and increase awareness in both sub regions, are key drivers. Government initiatives to improve cardiac care are prevalent in the GCC countries.

Current Trends: The GCC nations are quickly adopting advanced devices, including leadless pacemakers and integrated remote monitoring systems. South Africa is a significant market on the continent. The overall market faces challenges related to the high cost of devices and limited reimbursement policies in some African nations, making cost effective and conventional pacemakers more common in those areas.

Key Players

• The major players in the Cardiac Pacemaker Market are
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• BIOTRONIK SE & Co. KG
• LivaNova PLC
• MicroPort Scientific Corporation
• Oscor Inc.
• Pacetronix Ltd.
• MEDICO S.p.A.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM UP APPROACH
• 2.9 TOP DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SERVICE TYPES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL CARDIAC PACEMAKER MARKET OVERVIEW
• 3.2 GLOBAL CARDIAC PACEMAKER MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL CARDIAC PACEMAKER MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL CARDIAC PACEMAKER MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL CARDIAC PACEMAKER MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL CARDIAC PACEMAKER MARKET ATTRACTIVENESS ANALYSIS, BY TYPE
• 3.8 GLOBAL CARDIAC PACEMAKER MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL CARDIAC PACEMAKER MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
• 3.10 GLOBAL CARDIAC PACEMAKER MARKET ATTRACTIVENESS ANALYSIS, BY END USER
• 3.11 GLOBAL CARDIAC PACEMAKER MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.12 GLOBAL CARDIAC PACEMAKER MARKET, BY TYPE (USD BILLION)
• 3.13 GLOBAL CARDIAC PACEMAKER MARKET, BY APPLICATION (USD BILLION)
• 3.14 GLOBAL CARDIAC PACEMAKER MARKET, BY TECHNOLOGY (USD BILLION)
• 3.15 GLOBAL CARDIAC PACEMAKER MARKET, BY GEOGRAPHY (USD BILLION)
• 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL CARDIAC PACEMAKER MARKET EVOLUTION
• 4.2 GLOBAL CARDIAC PACEMAKER MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTERS FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE END USERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TYPE

• 5.1 OVERVIEW
• 5.2 MRI COMPATIBLE PACEMAKER
• 5.3 CONVENTIONAL PACEMAKER
• 5.4 IMPLANTABLE PACEMAKER
• 5.5 LEADLESS PACEMAKER
• 5.6 EXTERNAL PACEMAKER
• 5.7 BIVENTRICULAR CHAMBER

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 ARRHYTHMIA
• 6.3 ATRIAL FIBRILLATION
• 6.4 HEART BLOCK
• 6.5 LONG QT SYNDROME
• 6.6 CONGESTIVE HEART FAILURE

7 MARKET, BY TECHNOLOGY

• 7.1 OVERVIEW
• 7.2 SINGLE CHAMBER
• 7.3 DIAL CHAMBER
• 7.4 BIVENTRICULAR

8 MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 CARDIAC CENTERS
• 8.3 AMBULATORY SURGICAL CENTERS
• 8.4 HOSPITALS
• 8.5 CLINICS

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 U.S.
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 U.K.
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
  • 9.5.2 ARGENTINA
  • 9.5.3 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST AND AFRICA
  • 9.6.1 UAE
  • 9.6.2 SAUDI ARABIA
  • 9.6.3 SOUTH AFRICA
  • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY DEVELOPMENT STRATEGIES
• 10.3 COMPANY REGIONAL FOOTPRINT
• 10.4 ACE MATRIX
  • 10.4.1 ACTIVE
  • 10.4.2 CUTTING EDGE
  • 10.4.3 EMERGING
  • 10.4.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 OVERVIEW
• 11.2 MEDTRONIC PLC
• 11.3 ABBOTT LABORATORIES
• 11.4 BOSTON SCIENTIFIC CORPORATION
• 11.5 BIOTRONIK SE & CO. KG
• 11.6 LIVANOVA PLC
• 11.7 MICROPORT SCIENTIFIC CORPORATION
• 11.8 OSCOR, INC.
• 11.9 PACETRONIX LTD.
• 11.10 MEDICO S.P.A.